Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 703-710

  Fan, Qi ^a   Wang, Xuedi ^a   Zhang, Hanguang ^a   Li, Chuanwei ^a   Fan, Junhua ^a   Xu, Jing ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cathepsin S; Hepatocellular carcinoma; Invasion; RNA interference

Indexed keywords

CATHEPSIN S; SMALL INTERFERING RNA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CELL PROLIFERATION; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; SYNTHESIS;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CATHEPSINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84866000406     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.013     Document Type: Article

References (34)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
2. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998, 27:273-278.
3. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
4. Cabrera R., Nelson D.R. Review article: the management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2010, 31:461-476.
5. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
6. Tang Z.Y., Ye S.L., Liu Y.K., Qin L.X., Sun H.C., Ye Q.H., Wang L., Zhou J., Qiu S.J., Li Y., Ji X.N., Liu H., Xia J.L., Wu Z.Q., Fan J., Ma Z.C., Zhou X.D., Lin Z.Y., Liu K.D. A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130:187-196.
7. Spano D., Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin. Exp. Metastasis 2012, 29:381-395.
8. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
9. Liu S., Yu M., He Y., Xiao L., Wang F., Song C., Sun S., Ling C., Xu Z. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 2008, 47:1964-1973.
10. Chapman H.A., Riese R.J., Shi G.P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 1997, 59:63-88.
11. Reddy V.Y., Zhang Q.Y., Weiss S.J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 1995, 92:3849-3853.
12. Petanceska S., Canoll P., Devi L.A. Expression of rat cathepsin S in phagocytic cells. J. Biol. Chem. 1996, 271:4403-4409.
13. Arnlov J. Cathepsin S as a biomarker: where are we now and what are the future challenges?. Biomark. Med. 2012, 6:9-11.
14. Flannery T., Gibson D., Mirakhur M., McQuaid S., Greenan C., Trimble A., Walker B., McCormick D., Johnston P.G. The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 2003, 163:175-182.
15. Kos J., Sekirnik A., Kopitar G., Cimerman N., Kayser K., Stremmer A., Fiehn W., Werle B. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer 2001, 85:1193-1200.
16. Lindahl C., Simonsson M., Bergh A., Thysell E., Antti H., Sund M., Wikstrom P. Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. Cancer Genomics Proteomics 2009, 6:149-159.
17. Yang Y., Lim S.K., Choong L.Y., Lee H., Chen Y., Chong P.K., Ashktorab H., Wang T.T., Salto-Tellez M., Yeoh K.G., Lim Y.P. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J. Proteome Res. 2010, 9:4767-4778.
18. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Gene Dev. 2006, 20:543-556.
19. Xu J., Li D., Ke Z., Liu R., Maubach G., Zhuo L. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol. Med. Rep. 2009, 2:713-718.
20. Tian J., Tang Z.Y., Ye S.L., Liu Y.K., Lin Z.Y., Chen J., Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br. J. Cancer 1999, 81:814-821.
21. Rosso O., Piazza T., Bongarzone I., Rossello A., Mezzanzanica D., Canevari S., Orengo A.M., Puppo A., Ferrini S., Fabbi M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol. Cancer Res. 2007, 5:1246-1253.
22. Rodriguez L.G., Wu X., Guan J.L. Wound-healing assay. Methods Mol. Biol. 2005, 294:23-29.
23. Fu Y.G., Sung J.J., Wu K.C., Wu H.P., Yu J., Chan M., Chan V.Y., Chan K.K., Fan D.M., Leung W.K. Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants. Cancer Lett. 2005, 224:243-252.
24. Li F., Wang Z., Liu Y., Li J. Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol. Rep. 2010, 24:669-675.
25. Lim S.O., Park S.J., Kim W., Park S.G., Kim H.J., Kim Y.I., Sohn T.S., Noh J.H., Jung G. Proteome analysis of hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2002, 291:1031-1037.
26. Chen S.T., Pan T.L., Juan H.F., Chen T.Y., Lin Y.S., Huang C.M. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J. Proteome Res. 2008, 7:1379-1387.
27. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
28. Fernandez P.L., Farre X., Nadal A., Fernandez E., Peiro N., Sloane B.F., Shi G.P., Chapman H.A., Campo E., Cardesa A. Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 2001, 95:51-55.
29. Ryschich E., Lizdenis P., Ittrich C., Benner A., Stahl S., Hamann A., Schmidt J., Knolle P., Arnold B., Hammerling G.J., Ganss R. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 2006, 66:198-211.
30. Walker B., Lynas J.F., Meighan M.A., Bromme D. Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S. Biochem. Biophys. Res. Commun. 2000, 275:401-405.
31. Link J.O., Zipfel S. Advances in cathepsin S inhibitor design. Curr. Opin. Drug Discov. Devel. 2006, 9:471-482.
32. Burden R.E., Gormley J.A., Kuehn D., Ward C., Kwok H.F., Gazdoiu M., McClurg A., Jaquin T.J., Johnston J.A., Scott C.J., Olwill S.A. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie 2012, 94:487-493.
33. Yeh H.C., Lin S.M., Chen M.F., Pan T.L., Wang P.W., Yeh C.T. Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma. Hepatogastroenterology 2010, 57:98-102.
34. Bu W., Huang X., Tang Z. The role of MMP-2 in the invasion and metastasis of hepatocellular carcinoma (HCC). Zhonghua Yi Xue Za Zhi 1997, 77:661-664.